All In Biotech

BLA 761183 · Provention Bio INC

Tzield

Teplizumab-Mzwv · Injection · CD3-directed Antibody

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Nov 17, 2022

Approved uses

3

Original approval plus efficacy supplements

Registered trials

19

4 Phase 3, 7 recruiting

FAERS reports

720

100 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: Viral Reactivation Serious, life-threatening cases of viral reactivation, including Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation have been reported with TZIELD. Patients who are immunocompromised are at increased risk. Serious cases have also been reported in adults with higher body surface area or comorbid conditions, such as adrenal insufficiency or cardiovascular disease. The majority of serious cases occurred in patients who continued TZIELD treatment despite persistent, severe lymphopenia. Severe lymphopenia may be prolonged in adults. ( 5.1 , 5.4 ) Test patients for active EBV and CMV infection prior to starting treatment. TZIELD is contraindicated in patients who are immunocompromised or have active viral infection (such as EBV or CMV infection). Adhere to lymphocyte count monitoring requirements and discontinuation recommendations. Monitor patients...

What it is approved for

From the label in effect Nov 6, 2026.

TZIELD is indicated to [see Dosage and Administration (2.1) ]: Delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D. Delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 T1D. This indication is approved under accelerated approval based on evidence of reduced C-peptide decline [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Limitations of Use: There is limited evidence of safety and effectiveness in patients aged 45 years and older with Stage 2 T1D. TZIELD is not effective as a disease modifying therapy in non-autoimmune dysglycemic conditions . TZIELD is a CD3-directed antibody indicated to: ( 1 ) Delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients 1 year of age and older with Stage 2 T1D. Delay the decline in endogenous insulin production in pediatric patients aged 8 to 17 years recently diagnosed with Stage 3 T1D. This indication is approved under accelerated approval based on evidence of reduced C-peptide decline. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Limitations of Use : ( 1 ) There is limited evidence of safety and effectiveness in patients aged 45 years and older with Stage 2 T1D. TZIELD is not effective as a disease modifying therapy in non-autoimmune dysglycemic conditions.

Mechanism: Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 T1D in adult and pediatric patients aged 1 year and older with Stage 2 T1D and delays the decline in endogenous insulin production in patients aged 8 to 17 years recently diagnosed with Stage 3 T1D. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Teplizumab-mzwv leads to an increase in the proportion of regulatory T cells and of exhausted CD8+ T cells in peripheral blood.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 12, 2026 Supplement 10 · Efficacy · priority review OrphanLetterReviewLabel
  • Apr 20, 2026 Supplement 13 · Efficacy · priority review OrphanLetterLabel
  • Nov 17, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterMedication Guide
1 products under this application
  • TZIELD · TEPLIZUMAB-MZWV 2MG/2ML(1MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Teplizumab" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash166
  • nausea139
  • pyrexia120
  • fatigue119
  • vomiting92
  • headache86
  • lymphopenia62
  • lymphocyte count decreased55
  • chills51
  • rash pruritic44
  • pain42
  • pruritus41

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202378
2024173
2025205
2026264

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Tzield (Teplizumab-Mzwv) · HCPCS J9381

2024 spending

$404K

Beneficiaries

n/a

29 claims

Per beneficiary

n/a

2024 ASP limit $36.62 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$403,715

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 31 on PubMed

Sponsor: Provention Bio INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.